CNMV
Markets Directorate General
C/ Edison núm. 4
28006 Madrid

Madrid, 28 February 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

OTHER RELEVANT INFORMATION

The Company hereby submits the presentation to be exposed at the conference call with analysts and investors regarding the 2024 results, to be held today, Friday 28 February 2025, at 13:30 (CET).

To join the conference call, it is recommended to register at **this link** to receive access numbers and a personalized PIN.

To access the call without prior registration, use the following numbers: +34 919 01 16 44 (Spain), +1 646 233 4753 (USA) o +44 20 3936 2999 (UK). Conference number: 883194. Additionally, the presentation will be available for live streaming at **this link**.

FY 2024 Results Presentation

Madrid, February 28th 2025

AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSSINES UPDATE
3. Q&A & CLOSING REMARKS

José Luis Moreno
VP, Director Capital Markets and Investor Relations



AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSINESS UPDATE
3. Q&A & CLOSING REMARKS

Mª Luisa de Francia
Chief Financial Officer

Main financial figures

Revenues

Revenues evolution *(€ '000)*



Total revenues by product



Recurring revenues breakdown *(€ '000)*



2024 revenues breakdown by product *(€ mn)*



Key Financial Highlights

Main figures

(€ '000)	2023	2024	Var (%)
Revenues:			
Product sales	71,873	66,542	*-7.4%*
Licensing agreements	33,590	46,518	*38.5%*
Royalties	52,178	61,347	*17.6%*
Other	512	448	*-12.5%*
Total revenues	**158,153**	**174,855**	***10.6%***
Cost of Sales	-9,613	-8,183	*-14.9%*
Gross Profit	**148,540**	**166,672**	***12.2%***
Marketing expenses	-23,542	-22,809	*-3.1%*
General and administrative expenses	-18,263	-24,372	*33.5%*
Research and Development expenses	-99,302	-103,502	*4.2%*
Net impairment on financial assets	271	217	*-19.9%*
Other operating expenses	-12,783	-13,425	*5.0%*
Other results	1,252	3,687	*194.5%*
Operating profit	**-3,827**	**6,468**	***n.a.***
Net financial result	204	5,517	*n.a.*
Profit before tax	**-3,623**	**11,985**	***n.a.***
Income tax expense	4,760	14,140	*n.a.*
Net profit	**1,137**	**26,125**	***n.a.***

- **R&D increased 4%** to €103.5mn in 2024, related to the significant increase of the activity in both LAGOON and SaLuDo trials.
- **EBITDA reached €13mn** as of December 2024, compared to €2.1mn in December 2023.
- Total financial debt amounted to €47.8mn, with total cash and cash equivalents of €157mn. **Total net cash position** of €109mn as of December 2024.
- As of December 2024, the company has generated **€6.0mn in operating cash flow,** an increase of €19.5 million compared to the same period of the previous year (-€13.5mn as of December 2023).

ESG
Remarkable issues during FY24

- Publication of the Non-Financial Information Consolidated Statement and Sustainability Report according to CSRD and 11/2018 Spanish Law on non-financial information and diversity.

- Approval, by the Board of Directors, of the following issues:
    - Human Rights Policy
    - Biodiversity Policy
    - Sustainability Plan 2024-2026

- Net Zero Plan for the decarbonization of the company in 2050.

- Climate Risks and Opportunities Report.

AGENDA

1. FINANCIAL HIGHLIGHTS
2. BUSINESS UPDATE
3. Q&A & CLOSING REMARKS

Luis Mora
Managing Director

Pipeline – Expanding our Expertise in Oncology

			Phase 1	Phase 2	Phase 3	Market
Yondelis (trabectedin)	Soft tissue Sarcoma	Monotherapy	2nd/3rd line			
	Ovarian cancer	+ PLD (pegylated liposomal doxorubicin)	2nd/3rd line			
Aplidin (plitidepsin)	R/R Multiple Myeloma[1]	+ dexamethasone	3rd/4th line			
ZEPZELCA (lurbinectedin)	Small cell lung cancer	Monotherapy	2nd line US / other countries			
	Small cell lung cancer maintenance	+ atezolizumab	1st line maintenance			Roche / Jazz Pharmaceuticals
	Small cell lung cancer	Lurbi vs. lurbi+ irinotecan vs. topotecan or irinotecan	2nd line		LAGOON	
	Leiomyosarcoma	+ doxorubicin	1st line	Phase IIb/III		
	Small cell lung cancer	+ irinotecan	2nd line			
	Small cell lung cancer combo[2]	+ atezolizumab	2nd line			
Ecubectedin (PM14)	Solid tumours (basket trial)	Monotherapy				
	Solid tumours	Combination trials with IO				
	Soft tissue sarcoma[2]	Combination radiation				
PM534	Solid tumours	Monotherapy				
PM54	Solid tumours	Monotherapy				

(1) Approved in Australia
(2) IST – Investigator Sponsored Trial

Positive results from the IMforte Phase 3 clinical trial

Statistically significant and clinically meaningful OS & PFS benefit

- The combination of lurbinectedin and atezolizumab demonstrated a **positive, statistically significant and clinically meaningful improvement in the two primary endpoints of overall survival (OS) and progression-free survival (PFS).**
- PharmaMar will submit a **marketing authorization application** (MAA) to the EMA in the first half of 2025 to obtain the approval in Europe.
- Jazz will also submit a **supplemental New Drug Application** (sNDA) to the FDA.

Lurbinectedin
European Market Opportunity

Leiomyosarcoma

- **SaLuDo trial** (Phase IIb/II)
- 1st line therapy in combination with doxorubicin
- **End of recruitment expected** 1Q26
- **Longer treatment duration**

SCLC – 2nd line

- **LAGOON trial**
- 2nd line therapy
- Two arms:
  - Monotherapy
  - Combo with irino
- Recruitment ended 4Q24
- **Nothing approved in 2L since 1996**

SCLC – 1st line maint.

- **IMforte trial.**
- Combination of lurbinectedin + atezolizumab
- Longer treatment duration
- **Potential to be practice-changing**
- **Filing 1H25**

Lurbinectedin. Pathway to market in EU

Key events



Lurbinectedin: Commercial outlook

Global presence



European Union

PHM territories
- Western EU.

Commercial agreements
- UK, Scandinavia and Eastern Europe: Inmedica Pharma
- Greece, Cyprus and Balkans: Genesis Pharma

Rest of the world

Partner territories

US and rest of the word

Clinical development

Key pillars for sustainable growth

2025 → 2026 → 2027 → 2028

Potential indications:

PM14
(Ecubectedina)

- Small Cell Neuroendocrine High-Grade Prostate Cancer
- Combination IO on-going

PM54

- Potential 2nd generation of lurbinectedin
- Good safety profile
- Early signs of activity in solid tumors
- Phase I/II combos & monotherapy basket trial planned

PM534

- Unique / Novel tubulin inhibitor
- No neurotoxicity
- Early signs of activity in solid tumors
- Phase I/II combos & monotherapy planned

Phase III trials

Long-term sustainable value creation for our shareholders

Driving process across our strategic pillars



AGENDA

1. OPERATIONAL UPDATE
2. FINANCIAL HIGHLIGHTS
3. Q&A & CLOSING REMARKS

www.pharmamar.com